Cyllene Therapeutics
Reviewed active Updated Jul 8, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Cyllene Therapeutics (formerly known as EG 427) is a Paris-based clinical-stage genetic-medicines company developing localized, targeted DNA therapies using its proprietary HERMES platform, which employs a non-replicating herpes simplex virus type 1 (HSV-1) vector to deliver payloads to specific tissue types 123. The company’s lead candidate, EG110A, is being developed for severe neurogenic bladder conditions, having reduced urinary incontinence episodes by more than 88% in a Phase Ib/IIa trial for neurogenic detrusor overactivity; the company plans to initiate a Phase IIb/III study in 2027 and expand into overactive bladder and additional neurological indications including pain and migraine 23. The rebrand from EG 427 to Cyllene, announced with the Series C, references the birthplace of the Greek god Hermes, echoing the HERMES platform name 2.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-07 | Series C | €33M | M Ventures (Merck KGaA), GordonMD Global Investments | Bpifrance Investissement, existing investors 123 |
What Investors Say
“The HERMES platform represents a fundamentally differentiated approach to genetic medicine — one with the potential to address multiple high-burden neurological diseases with precision and durability.”
— Björn Kuhl, Principal at M Ventures, Cyllene Therapeutics Series C announcement, July 7, 2026 1
“With this funding, the company is positioned for global expansion, extending its pipeline into major neurological indications, including pain and migraine.”
— Craig Gordon, MD, Managing Member of GordonMD Global Investments, Cyllene Therapeutics Series C announcement, July 7, 2026 1
What Founders Say
“This financing marks a defining moment as we advance EG110A toward later-stage development and broaden our HERMES pipeline.”
— Philippe Chambon, President & CEO of Cyllene Therapeutics, quoted in Pharmaceutical Technology, July 7, 2026 2
“Early clinical data generated to date with EG110A support our belief that localized, targeted DNA medicines can deliver durable efficacy with a strong safety profile.”
— Philippe Chambon, President & CEO of Cyllene Therapeutics, Cyllene Series C announcement, July 7, 2026 1
Sources
-
The Pharma Navigator, “Cyllene Therapeutics Successfully Raises Millions to Advance Genetic Medicine Candidate,” July 7, 2026. Accessed July 2026. https://www.thepharmanavigator.com/news/cyllene-therapeutics-successfully-raises-millions-to-advance-genetic-medicine-candidate↩↩↩↩↩
-
Pharmaceutical Technology, “Merck KGaA-backed Cyllene Therapeutics secures €33m for gene therapy pipeline,” July 7, 2026. Accessed July 2026. https://www.pharmaceutical-technology.com/news/merck-kgaa-backed-cyllene-therapeutics-secures-e33m-for-gene-therapy-pipeline/↩↩↩↩↩
-
Manila Times / GlobeNewswire, “Cyllene Therapeutics (formerly known as EG 427) Raises €33 Million Series C Financing to Advance Clinical Development of EG110A and Pipeline Expansion,” July 7, 2026. Accessed July 2026. https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/cyllene-therapeutics-formerly-known-as-eg-427-raises-33-million-series-c-financing-to-advance-clinical-development-of-eg110a-and-pipeline-expansion/23795↩↩↩